Business Wire

Bloom Energy Enters Northern European Markets with New Sales Agreement

27.4.2023 16:15:00 EEST | Business Wire | Press release

Share

Bloom Energy (NYSE:BE) has signed an agreement with Elugie to provide a total of 9.75 megawatts (MW) of power from the Bloom Energy Server® at five commercial, industrial and data center sites in Belgium. It is Bloom’s first entry to the northern Europe market. Elugie, which has its headquarters in Riga, Latvia, with offices in Mechelen, Belgium, is an energy service company in the Benelux market of Belgium, the Netherlands and Luxembourg.

Bloom’s solid-oxide fuel cell platforms, to be delivered in late 2023 and early 2024, will include Bloom’s new compatibility with Combined Heat and Power (CHP) systems. Elugie and Bloom are in discussions about deploying additional Bloom energy platforms to sites in the Netherlands and the Baltic nations, comprised of Latvia, Lithuania and Estonia. Elugie is also in discussions with Bloom about the opportunity to deploy the hydrogen-producing Bloom Electrolyzer™.

The agreement with Elugie is another major step in Bloom’s expansion into Europe, following marketing partnership agreements with Telam for Spain and Portugal announced earlier this year, and energy platform sales to Cefla and Ferrari in Italy announced in 2022. It will be the largest deployment of Bloom’s new CHP feature, which is an important energy efficiency and climate-friendly technology for industrial and commercial electricity users in Europe.

“This is a big win in support of our focus to build international business sales,” said Tim Schweikert, Senior Managing Director of International Business Development, Bloom Energy. “We look forward to Elugie’s work in Belgium and the many markets that it serves. This builds on our activities to grow sales across Europe and also in target markets in Asia.”

“Elugie is proud of developing opportunities with Bloom for a total capacity of 9.75MW in Belgium,” says Bjorn Van Haver, founder, Elugie. “This partnership will bring utility-scale clean solutions to critical customers in the country. Our objective is also to deploy Bloom’s servers in the Netherlands and the Baltics. Elugie is an experienced EPC (engineering, procurement and construction company) in delivering energy-as-a-service.”

For more information about Bloom Energy’s CHP technology visit:
https://www.bloomenergy.com/applications/energy-server-with-heat-capture/

Forward-Looking Statements
This press release contains certain forward-looking statements that are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will” and “would” or the negative of these words or similar terms or expressions that concern Bloom’s expectations, strategy, priorities, plans or intentions. These forward-looking statements include, but are not limited to: Bloom’s expectations regarding collaboration with Elugie and/or its customers; any expected features, such as CHP, or benefits from or the size of the collaboration with Elugie or installations in northern Europe; Bloom’s international expansion plans; and Bloom’s long-term commitment to particular regions, policies or imperatives. More information on potential risks and uncertainties that may impact Bloom’s business are set forth in Bloom’s periodic reports filed with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 21, 2023 as well as subsequent reports filed with or furnished to the SEC from time to time. Bloom assumes no obligation to, and does not currently intend to, update any such forward-looking statements.

About Bloom Energy
Bloom Energy empowers businesses and communities to responsibly take charge of their energy. The company’s leading solid oxide platform for distributed generation of electricity and hydrogen is changing the future of energy. Fortune 100 companies around the world turn to Bloom Energy as a trusted partner to deliver lower carbon energy today and a net-zero future. For the latest news and announcements on Bloom Energy, visit https://newsroom.bloomenergy.com/.

For more information on Bloom Energy, visit https://www.bloomenergy.com/.

About Elugie
Since 2000, Elugie founder Bjorn Van Haver has been striving for a sustainable energy transition, for this and future generations. Elugie a pioneer in hydrogen power stations, where hydrogen is ingeniously converted into socially responsible electricity for buildings: more sustainable, smarter, more efficient, cheaper and autonomous from the grid. Elugie is renting power stations connected to the Elugie smart grid platform and green gas contracts. Elugie’s mission is to reduce costs, reduce carbon and maximize efficiency in compliance with the European Union taxonomy for sustainable activities. For more information, visit www.Elugie.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bloom Energy Media Contact:
Virginia Citrano
press@bloomenergy.com

Bloom Energy Investor Relations:
Ed Vallejo
267.370.9717
Edward.Vallejo@bloomenergy.com

Elugie Media Contact:
Bjorn Van Haver
info@elugie.be

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye